SCHEMBL15539682

SCHEMBL15539682

O=C(N1CCC(COc2ccc(Br)cc2)CC1)C1(C(F)(F)F)CCC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 3/20 0.53
MAOB P27338 2/20 0.53
EPHX2 P34913 2/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.42
GPR119 Q8TDV5 1/20 0.39
TACR3 P29371 1/20 0.39
PARP15 Q460N3 3/20 0.39
PARP10 Q53GL7 3/20 0.39
PARP2 Q9UGN5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15539038 0.95 AOC2 (0.57) AOC2MAOBEPHX2ALDH1A1CYP1A2
SCHEMBL15549958 0.91 AOC2 (0.47) AOC2MAOBEPHX2ALDH1A1CYP1A2
SCHEMBL15538620 0.86 AOC2 (0.47) AOC2MAOBEPHX2GPR119TACR3
SCHEMBL16757826 0.85 GPR119 (0.45) AOC2MAOBEPHX2ALDH1A1GPR119
SCHEMBL15538376 0.85 AOC2 (0.48) AOC2MAOBEPHX2GPR119TACR3
SCHEMBL15537989 0.84 AOC2 (0.47) AOC2MAOBEPHX2GPR119TACR3
SCHEMBL15538468 0.84 L3MBTL1 (0.42) AOC2MAOBEPHX2MAPTL3MBTL1
SCHEMBL15538543 0.83 AOC2 (0.49) AOC2MAOBEPHX2GPR119TACR3
SCHEMBL15538794 0.83 AOC2 (0.54) AOC2MAOBGPR119
SCHEMBL15539948 0.81 AOC2 (0.45) AOC2MAOBEPHX2GPR119TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP disclosed
EP-3074384-B1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-05-22 EP disclosed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 US disclosed
EP-3074384-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2016-10-05 EP disclosed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US disclosed
WO-2015080446-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-04 WO disclosed
EP-2858986-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2015-04-15 EP disclosed
WO-2013187646-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GPR84 AOC2 2528/4885MAOB 3220/4885EPHX2 1636/4885
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GLP1R AOC2 2053/4885MAOB 2668/4885EPHX2 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.